Insight into the structural requirement of aryl sulphonamide based gelatinases (MMP-2 and MMP-9) inhibitors – Part I: 2D-QSAR, 3D-QSAR topomer CoMFA and Naïve Bayes studies – First report of 3D-QSAR Topomer CoMFA analysis for MMP-9 inhibitors and jointly inhibitors of gelatinases together

References

• A. Gimeno, R. Beltrán-Debón, M. Mulero, G. Pujadas, and S. Garcia-Vallvé, Understanding the variability of the S1ʹ pocket to improve matrix metalloproteinase inhibitor selectivity profiles, Drug Discov. Today 25 (2020), pp. 38–57. doi:10.1016/j.drudis.2019.07.013.
   PubMed Web of Science ®Google Scholar
• T. Jha, N. Adhikari, A. Saha, and S.A. Amin, Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors, SAR QSAR Environ. Res. 29 (2018), pp. 43–68. doi:10.1080/1062936X.2017.
   PubMed Web of Science ®Google Scholar
• N. Cui, M. Hu, and R.A. Khalil, Biochemical and biological attributes of matrix metalloproteinases, Prog. Mol. Biol. Trans. Sci. 147 (2017), pp. 1–73. doi:10.1016/bs.pmbts.2017.02.005.
   PubMed Web of Science ®Google Scholar
• M. Raeeszadeh-Sarmazdeh, L.D. Do, and B.G. Hritz, Metalloproteinases and their inhibitors: Potential for the development of new therapeutics, Cells 9 (2020), pp. 1313. doi:10.3390/cells9051313.
   PubMed Web of Science ®Google Scholar
• K.W. Min, S.H. Lee, and S.J. Baek, Moonlighting proteins in cancer, Cancer Lett. 370 (2016), pp. 108–116. doi:10.1016/j.canlet.2015.09.022.
   PubMed Web of Science ®Google Scholar
• H. Laronha and J. Caldeira, Structure and function of human matrix metalloproteinases, Cells 9 (2020), pp. 1076. doi:10.3390/cells9051076.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Exploring in house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches, Struct. Chem. 29 (2018), pp. 285–297. doi:10.1007/s11224-017-1028-6.
   Web of Science ®Google Scholar
• Available at https://www.ebi.ac.uk/chembl. accessed 21 May 2021.
   Google Scholar
• K. Li, F.R. Tay, and C.K.Y. Yiu, The past, present and future perspectives of matrix metalloproteinase inhibitors, Pharmacol. Ther. 207 (2020), pp. 107465. doi:10.1016/j.pharmthera.2019.107465.
   PubMed Web of Science ®Google Scholar
• G.B. Fields, The rebirth of matrix metalloproteinase inhibitors: Moving beyond the dogma, Cells 8 (2019), pp. 984. doi:10.3390/cells8090984.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, A.K. Halder, S. Mallick, A. Saha, K.D. Saha, and T. Jha, Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays, Bioorg. Med. Chem. 24 (2016), pp. 4291–4309. doi:10.1016/j.bmc.2016.07.023.
   PubMed Web of Science ®Google Scholar
• D.L. Gossage, B. Cieslarová, S. Ap, H. Zheng, Y. Xin, P. Lal, G. Chen, V. Smith, and J.S. Sundy, Phase 1b study of the safety, pharmacokinetics, and disease-related outcomes of the matrix metalloproteinase-9 inhibitor andecaliximab in patients with rheumatoid arthritis, Clin. Ther. 40 (2018), pp. 156–165. doi:10.1016/j.clinthera.2017.11.011.
   PubMed Web of Science ®Google Scholar
• S. Das, S.A. Amin, and T. Jha, Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies, Eur. J. Med. Chem. 223 (2021), pp. 113623. doi:10.1016/j.ejmech.2021.113623.
   PubMed Web of Science ®Google Scholar
• F.X. Gomis-Rüth, Catalytic domain architecture of metzincin metalloproteases, J Biol. Chem. 284 (2009), pp. 15353–15357. doi:10.1074/jbc.R800069200.
   PubMed Web of Science ®Google Scholar
• A.K. Halder, A. Saha, and T. Jha, Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors, J. Pharm. Pharmacol. 65 (2013), pp. 1541–1554. doi:10.1111/jphp.12133.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Structural exploration for the refinement of anticancer matrix metalloproteinase-2 inhibitor designing approaches through robust validated multi-QSARs, J. Mol. Struct. 1156 (2018), pp. 501–515. doi:10.1016/j.molstruc.2017.12.005.
   Web of Science ®Google Scholar
• S. Sanyal, S.A. Amin, N. Adhikari, and T. Jha, QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors, SAR QSAR Environ. Res. 30 (2019), pp. 247–263. doi:10.1080/1062936X.2019.1588159.
   PubMed Web of Science ®Google Scholar
• S. Mondal, S. Banerjee, S.A. Amin, and T. Jha, Structural analysis of arylsulfonamide-based carboxylic acid derivatives: A QSAR study to identify the structural contributors toward their MMP-9 inhibition, Struct. Chem. 32 (2021), pp. 417–430. doi:10.1007/s11224-020-01635-4.
   Web of Science ®Google Scholar
• J. Verma, V.M. Khedkar, and E.C. Coutinho, 3D-QSAR in drug design–a review, Curr. Top. Med. Chem. 10 (2010), pp. 95–115. doi:10.2174/156802610790232260.
   PubMed Web of Science ®Google Scholar
• A. Cherkasov, E.N. Muratov, D. Fourches, A. Varnek, I.I. Baskin, M. Cronin, J. Dearden, P. Gramatica, Y.C. Martin, R. Todeschini, V. Consonni, V.E. Kuz’min, R. Cramer, R. Benigni, C. Yang, J. Rathman, L. Terfloth, J. Gasteiger, A. Richard, and A. Tropsha, QSAR modeling: Where have you been? Where are you going to? J. Med. Chem. 57 (2014), pp. 4977–5010. doi:10.1021/jm4004285.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer, S. Riahi, M.R. Ganjali, and P. Norouzi, QSAR study of C allosteric binding site of HCV NS5B polymerase inhibitors by support vector machine, Mol. Divers. 15 (2011), pp. 645–653. doi:10.1007/s11030-010-9283-0.
   PubMed Web of Science ®Google Scholar
• R. Ragno, A web portal that brings 3-D QSAR to all electronic devices—the Py-CoMFA web application as tool to build models from pre-aligned datasets, J. Comput. Aided Mol. Des. 33 (2019), pp. 855–864. doi:10.1007/s10822-019-00231-x.
   PubMed Web of Science ®Google Scholar
• K. Roy, S. Kar, and R.N. Das, A Primer on QSAR/QSPR Modeling: Fundamental Concepts, Springer, New York, 2015.
   Google Scholar
• A.A. Toropov, A.P. Toropova, G. Selvestrel, D. Baderna, and E. Benfenati, Prediction of no observed adverse effect concentration for inhalation toxicity using Monte Carlo approach, SAR QSAR Environ. Res. 31 (2020), pp. 1–12. doi:10.1080/1062936X.2020.1841827.
   PubMed Web of Science ®Google Scholar
• V.V. Kleandrova, M.T. Scotti, L. Scotti, A. Nayarisseri, and A. Speck-Planche, Cell-based multi-target QSAR model for design of virtual versatile inhibitors of liver cancer cell lines, SAR QSAR Environ. Res. 31 (2020), pp. 815–836. doi:10.1080/1062936X.2020.1818617.
   PubMed Web of Science ®Google Scholar
• Z.Y. Algamal, M.K. Qasim, M.H. Lee, and H.T.M. Ali, QSAR model for predicting neuraminidase inhibitors of influenza A viruses (H1N1) based on adaptive grasshopper optimization algorithm, SAR QSAR Environ. Res. 31 (2020), pp. 803–814. doi:10.1080/1062936X.2020.1818616.
   PubMed Web of Science ®Google Scholar
• P. Kumar and A. Kumar, In silico enhancement of azo dye adsorption affinity for cellulose fibre through mechanistic interpretation under guidance of QSPR models using Monte Carlo method with index of ideality correlation, SAR QSAR Environ. Res. 31 (2020), pp. 697–715. doi:10.1080/1062936X.2020.1806105.
   PubMed Web of Science ®Google Scholar
• J. Devillers, Methods for building QSARs, Methods Mol. Biol. 930 (2013), pp. 3–27. doi:10.1007/978-1-62703-059-5_1.
   PubMedGoogle Scholar
• H. Verma, S. Choudhary, M. Kumar, and O. Silakari, In silico guided design of non-covalent inhibitors of DprE1: Synthesis and biological evaluation, SAR QSAR Environ. Res. 32 (2021), pp. 333–352. doi:10.1080/1062936X.2021.1900390.
   PubMed Web of Science ®Google Scholar
• V.H. Masand, V. Rastija, M.K. Patil, A. Gandhi, and A. Chapolikar, Extending the identification of structural features responsible for anti-SARS-CoV activity of peptide-type compounds using QSAR modelling, SAR QSAR Environ. Res. 31 (2020), pp. 643–654. doi:10.1080/1062936X.2020.1784271.
   PubMed Web of Science ®Google Scholar
• A. Scozzafava and C.T. Supuran, Protease inhibitors: Synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions, Bioorg. Med. Chem. Lett. 12 (2002), pp. 2667–2672. doi:10.1016/s0960-894x(02)00564-4.
   PubMed Web of Science ®Google Scholar
• A. Scozzafava and C.T. Supuran, Carbonic anhydrase and matrix metalloproteinase inhibitors: Sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes, J. Med. Chem. 43 (2000), pp. 3677–3687. doi:10.1021/jm000027t.
   PubMed Web of Science ®Google Scholar
• A. Scozzafava and C.T. Supuran, Protease inhibitors: Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties, J. Med. Chem. 43 (2000), pp. 1858–1865. doi:10.1021/jm990594k.
   PubMed Web of Science ®Google Scholar
• ChemDraw Ultra 5.0, Cambridge Soft Corporation, USA, 2010.
   Google Scholar
• C.W. Yap, PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem 32 (2011), pp. 1466–1474. doi:10.1002/jcc.21707.
   PubMed Web of Science ®Google Scholar
• M. Shahlaei, Descriptor selection methods in quantitative structure-activity relationship studies: A review study, Chem. Rev. 113 (2013), pp. 8093–8103. doi:10.1021/cr3004339.
   PubMed Web of Science ®Google Scholar
• V.N. Vapnik, The Nature of Statistical Learning Theory, 2nd ed., Springer, New York, 2000.
   Google Scholar
• QSAR Tools, DTC Laboratory, India, 2015; Software available at https://dtclab.webs.com/software-tools accessed 22 January 2021.
   Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2! J. Mol. Graph Model. 20 (2002), pp. 269–276. doi:10.1016/s1093-3263(01)00123-1.
   PubMed Web of Science ®Google Scholar
• F. Sadeghi, A. Afkhami, T. Madrakian, and R. Ghavami, Computational study on subfamilies of piperidine derivatives: QSAR modelling, model external verification, the inter-subset similarity determination, and structure-based drug designing, SAR QSAR Environ. Res. 32 (2021), pp. 433–462. doi:10.1080/1062936X.2021.1891568.
   PubMed Web of Science ®Google Scholar
• D. Kovács, P. Király, and G. Tóth, Sample-size dependence of validation parameters in linear regression models and in QSAR, SAR QSAR Environ. Res. 32 (2021), pp. 247–268. doi:10.1080/1062936X.2021.1890208.
   PubMed Web of Science ®Google Scholar
• C. Nantasenamat, A. Worachartcheewan, S. Prachayasittikul, C. Isarankura-Na-Ayudhya, and V. Prachayasittikul, QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole, Eur. J. Med. Chem. 69 (2013), pp. 99–114. doi:10.1016/j.ejmech.2013.08.015.
   PubMed Web of Science ®Google Scholar
• T.C. Smith and E. Frank, Introducing machine learning concepts with WEKA, Methods Mol. Biol. 1418 (2016), pp. 353–378. doi:10.1007/978-1-4939-3578-9_17.
   PubMedGoogle Scholar
• J. Tong, D. Luo, X. Zhang, and S. Bian, Design of novel SHP2 inhibitors using topomer CoMFA, HQSAR analysis, and molecular docking, Struct. Chem. 32 (2021), pp. 1061–1076. doi:10.1007/s11224-020-01677-8.
   Web of Science ®Google Scholar
• D.M. Chhatbar, U.J. Chaube, V.K. Vyas, and H.G. Bhatt, CoMFA, CoMSIA, topomer CoMFA, HQSAR, molecular docking and molecular dynamics simulations study of triazine morpholino derivatives as mTOR inhibitors for the treatment of breast cancer, Comput. Biol. Chem. 80 (2019), pp. 351–363. doi:10.1016/j.compbiolchem.2019.04.017.
   PubMed Web of Science ®Google Scholar
• J. Tong, F. Yi, D. Luo, and T. Wang, QSAR studies of sulfonamide hydroxamates derivatives as mmp-2 inhibitors topomer CoMFA and molecular docking, Lett. Drug Des. Discov. 17 (2020), pp. 1364–1371. doi:10.2174/1570180817999200630124920.
   Web of Science ®Google Scholar
• B. Niu, Y. Lu, J. Wang, Y. Hu, J. Chen, Q. Chen, G. He, and L. Zheng, 2D-SAR, topomer CoMFA and molecular docking studies on avian influenza neuraminidase inhibitors, Comput. Struct. Biotechnol. J. 17 (2018), pp. 39–48. doi:10.1016/j.csbj.2018.11.007.
   PubMed Web of Science ®Google Scholar
• SYBYL-X 2.0. Tripos Inc, St. Louis, MO, 2015; Software available at http://www.certara.com
   Google Scholar
• L. Wang, L. Chen, Z. Liu, M. Zheng, Q. Gu, and J. Xu, Predicting mTOR inhibitors with a classifier using recursive partitioning and Naïve Bayesian approaches, PLoS One 9 (2014), pp. e95221. doi:10.1371/journal.pone.0095221.
   PubMed Web of Science ®Google Scholar
• L. Chen, Y. Li, Q. Zhao, H. Peng, and T. Hou, ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques, Mol. Pharm. 8 (2011), pp. 889–900. doi:10.1021/mp100465q.
   PubMed Web of Science ®Google Scholar
• H. Zhang, L. Ding, Y. Zou, S.Q. Hu, H.G. Huang, W.B. Kong, and J. Zhang, Predicting drug-induced liver injury in human with Naïve Bayes classifier approach, J. Comput. Aided Mol. Des. 30 (2016), pp. 889–898. doi:10.1007/s10822-016-9972-6.
   PubMed Web of Science ®Google Scholar
• L.L. Liu, J. Lu, Y. Lu, M.Y. Zheng, X.M. Luo, W.L. Zhu, H.L. Jiang, and K.X. Chen, Novel Bayesian classification models for predicting compounds blocking hERG potassium channels, Acta Pharmacol. Sin. 35 (2014), pp. 1093–1102. doi:10.1038/aps.2014.35.
   PubMed Web of Science ®Google Scholar
• D. Rogers and M. Hahn, Extended-connectivity fingerprints, J. Chem. Inf. Model. 50 (2010), pp. 742–754. doi:10.1021/ci100050t.
   PubMed Web of Science ®Google Scholar
• D. Rogers, R.D. Brown, and M. Hahn, Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up, J. Biomol. Screen. 10 (2005), pp. 682–686. doi:10.1177/1087057105281365.
   PubMed Web of Science ®Google Scholar
• Discovery studio 3.0. Accelrys Inc., San Diego, USA, 2015; Software available at http://www.accelrys.com
   Google Scholar
• T. Fawcett, An introduction to ROC analysis, Patt. Recogn. Lett. 27 (2006), pp. 861–874. doi:10.1016/j.patrec.2005.10.010.
   Web of Science ®Google Scholar
• R. Todeschini and V. Consonni, Molecular Descriptors for Cheminformatics, 2nd ed., Vol. 2, Wiley, Weinheim, 2009.
   Google Scholar
• E. Pourbasheer, S. Vahdani, D. Malekzadeh, R. Aalizadeh, and A. Ebadi, QSAR study of 17β-HSD3 inhibitors by genetic algorithm-support vector machine as a target receptor for the treatment of prostate cancer, Iran. J. Pharm. Res. 16 (2017), pp. 966–980.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959–5967. doi:10.1021/ja00226a005.
   PubMed Web of Science ®Google Scholar
• S.L. Dixon, A.M. Smondyrev, E.H. Knoll, S.N. Rao, D.E. Shaw, and R.A. Friesner, PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results, J. Comput. Aided Mol. Des. 20 (2006), pp. 647–671. doi:10.1007/s10822-006-9087-6.
   PubMed Web of Science ®Google Scholar
• R.D. Cramer, Topomer CoMFA: A design methodology for rapid lead optimization, J. Med. Chem. 46 (2003), pp. 374–388. doi:10.1021/jm020194o.
   PubMed Web of Science ®Google Scholar
• B. Wendt, M. Mulbaier, S. Wawro, C. Schultes, J. Alonso, B. Janssen, and J. Lewis, Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: Alleviating drug-drug interactions through use of PubChem data and comparative molecular field analysis guided synthesis, J. Med. Chem. 54 (2011), pp. 3982–3986. doi:10.1021/jm200272h.
   PubMed Web of Science ®Google Scholar
• B. Sepehri and R. Ghavami, Design of new CD38 inhibitors based on CoMFA modelling and molecular docking analysis of 4-amino-8-quinoline carboxamides and 2,4-diamino-8-quinazoline carboxamides, SAR QSAR Environ. Res. 30 (2019), pp. 21–38. doi:10.1080/1062936X.2018.1545695.
   PubMed Web of Science ®Google Scholar
• J. Zheng, R. Wen, and D. Guillaume, Three-dimensional quantitative structure-activity relationship (CoMFA and CoMSIA) studies on galardin derivatives as gelatinase A (matrix metalloproteinase 2) inhibitors, J. Enzyme. Inhib. Med. Chem. 23 (2008), pp. 445–453. doi:10.1080/14756360701632221.
   PubMed Web of Science ®Google Scholar
• L. Xi, J. Du, S. Li, J. Li, H. Liu, and X. Yao, A combined molecular modeling study on gelatinases and their potent inhibitors, J. Comput. Chem 31 (2010), pp. 24–42. doi:10.1002/jcc.21279.
   PubMed Web of Science ®Google Scholar
• K.M. Turra, D.P. Rivelli, S.B. de Moraes Barros, and K.F.M. Pasqualoto, Predicting novel antitumor agents: 3D-pharmacophore mapping of β-n-biaryl ether sulfonamide-based hydroxamates as potentially MMP-2 inhibitors, Mol. Inf. 33 (2014), pp. 573–587. doi:10.1002/minf.201400073.
   PubMed Web of Science ®Google Scholar
• X.Q. Yan, Z.C. Wang, Z. Li, P.F. Wang, H.Y. Qiu, L.W. Chen, X.Y. Lu, P.C. Lv, and H.L. Zhu, Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis, Bioorg. Med. Chem. Lett. 25 (2015), pp. 4664–4671. doi:10.1016/j.bmcl.2015.08.026.
   PubMed Web of Science ®Google Scholar
• J. Zhang, X.J. Wang, Z.K. Dong, S.Q. Wang, W.R. Xu, J.W. Fu, X.C. Cheng, and R.L. Wang, CoMFA/CoMSIA and molecular docking studies of novel matrix metalloproteinase- 2 inhibitors based on L-tyrosine scaffold, Lett. Drug Des. Discov. 13 (2016), pp. 376–386. doi:10.2174/1570180812666150923235104.
   Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Understanding chemico-biological interactions of glutamate MMP-2 inhibitors through rigorous alignment-dependent 3D-QSAR analyses, ChemistrySelect 2 (2017), pp. 7888–7898. doi:10.1002/slct.201701330.
   Web of Science ®Google Scholar
• D. Rathee, V. Lather, and H. Dureja, Pharmacophore modeling and 3D QSAR studies for prediction of matrix metalloproteinases inhibitory activity of hydroxamate derivatives, Biotechnol. Res. Innov. 1 (2017), pp. 112–122. doi:10.1016/j.biori.2017.10.002.
   Google Scholar
• Z.C. Wang, F.Q. Shen, M.R. Yang, L.X. You, L.Z. Chen, H.L. Zhu, Y.D. Lu, F.L. Kong, and M.H. Wang, Dihydropyrazothiazole derivatives as potential MMP-2/MMP-8 inhibitors for cancer therapy, Bioorg. Med. Chem. Lett. 28 (2018), pp. 3816–3821. doi:10.1016/j.bmcl.2018.05.004.
   PubMedGoogle Scholar
• S. Kalva, D. Vinod, and L.M. Saleena, Field- and Gaussian-based 3D-QSAR studies on barbiturate analogs as MMP-9 inhibitors, Med. Chem. Res. 22 (2013), pp. 5303–5313. doi:10.1007/s00044-013-0479-6.
   Web of Science ®Google Scholar
• D. Rathee, V. Lather, and H. Dureja, Prediction of MMP-9 inhibitory activity of N-hydroxy-α-phenylsulfonylacetamide derivatives by pharmacophore based modeling and 3-D QSAR studies, Porto. Biomed. J. 3 (2018), pp. e6. doi:10.1016/j.pbj.0000000000000006.
   PubMedGoogle Scholar
• S. Jana and S.K. Singh, Identification of selective MMP-9 inhibitors through multiple e-pharmacophore, ligand-based pharmacophore, molecular docking, and density functional theory approaches, J. Biomol. Struct. Dyn. 37 (2019), pp. 944–965. doi:10.1080/07391102.2018.1444510.
   PubMed Web of Science ®Google Scholar
• K. Roy, D.K. Pal, A.U. De, and C. Sengupta, QSAR of matrix metalloproteinase inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates using LFER model, Drug Des. Discov. 17 (2001), pp. 315–323.
   PubMedGoogle Scholar
• D. Kumar and S.P. Gupta, A quantitative structure–activity relationship study on some matrix metalloproteinase and collagenase inhibitors, Bioorg. Med. Chem. 11 (2003), pp. 421–426. doi:10.1016/s0968-0896(02)00438-8.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta, D. Kumar, and S. Kumaran, A quantitative structure–activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines, Bioorg. Med. Chem. 11 (2003), pp. 1975–1981. doi:10.1016/s0968-0896(03)00069-5.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta, V. Maheswaran, V. Pande, and D. Kumar, A comparative QSAR study on carbonic anhydrase and matrix metalloproteinase inhibition by sulfonylated amino acid hydroxamates, J. Enzyme. Inhib. Med. Chem. 18 (2003), pp. 7–13. doi:10.1080/1475636021000049735.
   PubMed Web of Science ®Google Scholar
• M. Fernández, J. Caballero, and A. Tundidor-Camba, Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives as matrix metalloproteinase inhibitors, Bioorg. Med. Chem. 14 (2006), pp. 4137–4150. doi:10.1016/j.bmc.2006.01.072.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: Hydroxamic acid analogs, Med. Chem. 2 (2006), pp. 243–250. doi:10.2174/157340606776930790.
   PubMedGoogle Scholar
• R.P. Verma and C. Hansch, Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs, Bioorg. Med. Chem. 15 (2007), pp. 2223–2268. doi:10.1016/j.bmc.2007.01.011.
   PubMed Web of Science ®Google Scholar
• O. Nicolotti, M. Catto, I. Giangreco, M. Barletta, F. Leonetti, A. Stefanachi, L. Pisani, S. Cellamare, P. Tortorella, F. Loiodice, and A. Carotti, Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9, Eur. J. Med. Chem. 58 (2012), pp. 368–376. doi:10.1016/j.ejmech.2012.09.036.
   PubMed Web of Science ®Google Scholar
• R.P. Verma, A. Kurup, and C. Hansch, On the role of polarizability in QSAR, Bioorg. Med. Chem. 13 (2005), pp. 237–255. doi:10.1016/j.bmc.2004.09.039.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, A quantitative structure–activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors, Bioorg. Med. Chem. 13 (2005), pp. 5454–5462. doi:10.1016/j.bmc.2005.05.055.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: Bicyclic heteroaryl hydroxamic acid analogs, Lett. Drug Des. Discov. 2 (2005), pp. 522–528. doi:10.2174/157018005774479096.
   Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: Piperazine, piperidine and diazepine hydroxamic acid analogs, Asian J. Biochem. 1 (2006), pp. 211–223. doi:10.3923/ajb.2006.211.223.
   Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studie s on benzodiazepine hydroxamic acid inhibitors of matrix metalloproteinases an d tumor necrosis factor-α converting enzyme, Asian J. Biochem. 1 (2006), pp. 47–56. doi:10.3923/ajb.2006.47.56.
   Google Scholar
• M. Fernández and J. Caballero, QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamide derivatives, Bioorg. Med. Chem. 15 (2007), pp. 6298–626310. doi:10.1016/j.bmc.2007.06.014.
   PubMed Web of Science ®Google Scholar